120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
高载药量二氢杨梅素仿生纳米乳通过抑制肝脏铁死亡改善早期非酒精性脂肪性肝病
Authors Yin M, Tian M, Wang W, Shi C, Fang J, Xiong W
Received 16 October 2025
Accepted for publication 23 January 2026
Published 4 February 2026 Volume 2026:21 570903
DOI https://doi.org/10.2147/IJN.S570903
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Lijie Grace Zhang
Mingxing Yin,* Maoxian Tian,* Wenqing Wang, Chunyang Shi, Jianguo Fang, Wei Xiong
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wei Xiong, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China, Email xiongv@tjh.tjmu.edu.cn
Introduction: Nonalcoholic fatty liver disease (NAFLD) is a metabolic disorder characterized by lipid accumulation in the liver, and is often linked to ferroptosis, an iron-dependent programmed cell death driven by lipid peroxidation. Dihydromyricetin (DMY), a flavonoid from Ampelopsis grossedentata, exhibits anti-NAFLD efficiency but has low bioavailability. In this study, a high DMY-loaded biomimetic nanoemulsion (DMY-bNE) was developed using a double emulsification method with glyceryl monooleate.
Methods: DMY-bNE was characterized in vitro and in vivo including encapsulation efficiency (EE), drug-loading capacity (DLE), gastrointestinal (GI) absorption, biodistribution, pharmacokinetics, safety. High fat diet induced NAFLD mouse model was used to investigate the therapeutic effect and mechanism.
Results: DMY-bNE showed high EE (99.5%) and DLE (24.9%), promoted GI absorption, enhanced liver accumulation, improved pharmacokinetic properties and good in vivo safety. In NAFLD mice, DMY-bNE significantly ameliorated the disease progression by inhibiting hepatic ferroptosis.
Conclusion: These findings demonstrated that DMY-bNE combines enhanced drug delivery with ferroptosis inhibition, thereby offering a promising strategy for NAFLD therapy.
Keywords: dihydromyricetin, biomimetic nanoemulsion, nonalcoholic fatty liver disease, high drug loading, ferroptosis
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Wei Xiong, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China, Email xiongv@tjh.tjmu.edu.cn
Introduction: Nonalcoholic fatty liver disease (NAFLD) is a metabolic disorder characterized by lipid accumulation in the liver, and is often linked to ferroptosis, an iron-dependent programmed cell death driven by lipid peroxidation. Dihydromyricetin (DMY), a flavonoid from Ampelopsis grossedentata, exhibits anti-NAFLD efficiency but has low bioavailability. In this study, a high DMY-loaded biomimetic nanoemulsion (DMY-bNE) was developed using a double emulsification method with glyceryl monooleate.
Methods: DMY-bNE was characterized in vitro and in vivo including encapsulation efficiency (EE), drug-loading capacity (DLE), gastrointestinal (GI) absorption, biodistribution, pharmacokinetics, safety. High fat diet induced NAFLD mouse model was used to investigate the therapeutic effect and mechanism.
Results: DMY-bNE showed high EE (99.5%) and DLE (24.9%), promoted GI absorption, enhanced liver accumulation, improved pharmacokinetic properties and good in vivo safety. In NAFLD mice, DMY-bNE significantly ameliorated the disease progression by inhibiting hepatic ferroptosis.
Conclusion: These findings demonstrated that DMY-bNE combines enhanced drug delivery with ferroptosis inhibition, thereby offering a promising strategy for NAFLD therapy.
Keywords: dihydromyricetin, biomimetic nanoemulsion, nonalcoholic fatty liver disease, high drug loading, ferroptosis